Comprehensive analysis of the novel omicron receptor AXL in cancers

Zhang, Weina; Li, Xueping; Wang, Pengfei; Li, Zhu; Xiao, Xinhua; Dai, Yong

doi:10.1016/j.csbj.2022.06.051

Cited by 6 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, a study indicated that AXL could independently mediate the omicron infection (43). In our study, the level of serum AXL not only is correlated with the development of COVID-19, but also can provide early warning of clinical deterioration in the first week after infection, suggesting that it is a superior biomarker for COVID-19.…”

Section: Discussionmentioning

confidence: 52%

Serum AXL is a potential molecular marker for predicting COVID-19 progression

You,

Huang,

Zhong

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundThe severity, symptoms, and outcome of COVID-19 is thought to be closely linked to how the virus enters host cells. This process involves the key roles of angiotensin-converting enzyme 2 (ACE2) and the Tyrosine protein kinase receptor UFO (AXL) receptors. However, there is limited research on the circulating levels of ACE2 and AXL and their implications in COVID-19.MethodsA control group of 71 uninfected individuals was also included in the study. According to the Guidance for Corona Virus Disease 2019 (10th edition), a cohort of 358 COVID-19 patients were categorized into non-severe and severe cases. Serum ACE2/AXL levels in COVID-19 patients were detected by enzyme-linked immunosorbent assay (ELISA) at different time points post-COVID-19 infection, including days 0-7, 8-15, 31-179 and >180 days. Serum SARS-CoV-2 IgG/IgM antibodies in COVID-19 patients at the same intervals were assessed by using an iFlash 3000 Chemiluminescence Immunoassay Analyzer. The receiver operating characteristic (ROC) curves were used to assess the diagnostic value of the biological markers, and the association between laboratory parameters and illness progression were explored.ResultsCompared with the uninfected group, the levels of ACE2 and AXL in the COVID-19 group were decreased, and the SARS-COV-2 IgG level was increased. AXL (AUC = 0.774) demonstrated a stronger predictive ability for COVID-19 than ACE2. In the first week after infection, only the level of AXL was statistically different between severe group and non-severe group. After first week, the levels of ACE2 and AXL were different in two groups. Moreover, in severe COVID-19 cases, the serum ACE2, AXL, and SARS-COV-2 IgM levels reached a peak during days 8–15 before declining, whereas serum SARS-COV-2 IgG levels continued to rise, reaching a peak at day 31-180 days before decreasing. In addition, the AXL level continued to decrease and the SARS-COV-2 IgG level continued to increase in the infected group after 180 days compared to the uninfected group.ConclusionsThe levels of serum ACE2 and AXL correlate with COVID-19 severity. However, AXL can also provide early warning of clinical deterioration in the first week after infection. AXL appears to be a superior potential molecular marker for predicting COVID-19 progression.

show abstract

Section: Discussionmentioning

confidence: 52%

Serum AXL is a potential molecular marker for predicting COVID-19 progression

You,

Huang,

Zhong

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Moreover, apart from ACE2, the transmembrane protein AXL has been recognized for its involvement in several vital biological processes, including cell growth, migration, aggregation, metastasis, and adhesion. Importantly, this protein holds significant relevance in both the pathogenesis of COVID-19 and the advancement of cancer [ 25 ]. Moreover, recent studies have unveiled a correlation between elevated ACE2 expression and enhanced overall survival in diverse malignancies, including esophageal carcinoma.…”

Section: Discussionmentioning

confidence: 99%

A SARS-CoV-2 related signature that explores the tumor microenvironment and predicts immunotherapy response in esophageal squamous cell cancer

Ren,

Zhang,

Zhang

et al. 2023

Aging

View full text Add to dashboard Cite

Background: The existing therapeutic approaches for combating tumors are insufficient in completely eradicating malignancy, as cancer facilitates tumor relapse and develops resistance to treatment interventions. The potential mechanistic connection between SARS-CoV-2 and ESCC has received limited attention. Therefore, our objective was to investigate the characteristics of SARS-CoV-2-related-genes (SCRGs) in esophageal squamous cancer (ESCC). Methods: Raw data were obtained from the TCGA and GEO databases. Clustering of SCRGs from the scRNA-seq data was conducted using the Seurat R package. A risk signature was then generated using Lasso regression, incorporating prognostic genes related to SCRGs. Subsequently, a nomogram model was developed based on the clinicopathological characteristics and the risk signature. Results: Eight clusters of SCRGs were identified in ESCC utilizing scRNA-seq data, of which three exhibited prognostic implications. A risk signature was then made up with bulk RNA-seq, which displayed substantial correlations with immune infiltration. The novel signature was verified to have excellent prognostic efficacy. Conclusion: The utilization of risk signatures based on SCRGs can efficiently forecast the prognosis of ESCC. A thorough characterization of the SCRGs signature in ESCC could facilitate the interpretation of ESCC's response to immunotherapy and offer innovative approaches to cancer therapy.

show abstract

“…The databases including the Consensus and HPA datasets were used to compare the RNA expression level of PTP1B among different tissues and FANTOM5 dataset was used to compare the protein expression level of PTP1B among those tissues ( 11 ). In addition, the single-cell RNA-sequencing (scRNA-seq) of different tissues was analyzed ( 12 , 13 ). First, quality control of cells used to scRNA-seq should be single suspension cells without pre-enrichment.…”

Section: Methodsmentioning

confidence: 99%

Multi-omics analyses of tumor-associated immune-infiltrating cells with the novel immune checkpoint protein tyrosine phosphatase 1B (PTP1B) in extracellular matrix of brain-lower-grade-glioma (LGG) and uveal-melanoma (UVM)

et al. 2022

Self Cite

View full text Add to dashboard Cite

Immune checkpoint inhibitors represented by PD-1 have greatly changed the way cancer is treated. In addition to PD-1, new immune checkpoints are constantly excavated to better treat cancer. Recently, protein tyrosine phosphatase 1B (PTP1B) was identified as a new immune checkpoint and played a critical role in the treatment of tumors by inhibiting the proliferation and cytotoxicity of T cells induced by tumor antigen. To explore the targeting role of PTP1B in precision tumor therapy, we deeply analyzed the expression and prognosis of PTP1B in all tumors. Survival analysis results indicated that PTP1B was highly expressed in most tumor tissues and indicated poor prognosis in acute-myeloid-leukemia (LAML), brain-lower-grade-glioma (LGG), kidney-renal clear-cell-carcinoma (KIRC) and uveal-melanoma (UVM). The methylation status of PTP1B in these four tumors exhibited hypomethylation and mutation landscape showed that PTP1B had its specific characteristics in genomic instability and heterogeneity. The homologous recombination deficiency (HRD) and loss of heterozygosity (LOH) were positive related to PTP1B expression in liver-hepatocellular-carcinoma (LIHC) and kidney-chromophobe (KICH), while the immunescore and immune infiltration displayed a significant positive correlation with PTP1B expression in LGG and UVM. Drug sensitivity tests showed that the PTP1B inhibitor MSI-1436 had a sensitivity effect suppressing tumor cell viability and suggested it enhanced the efficacy of PD-1 inhibitors in cancers.

show abstract

Comprehensive analysis of the novel omicron receptor AXL in cancers

Cited by 6 publications

References 29 publications

Serum AXL is a potential molecular marker for predicting COVID-19 progression

Serum AXL is a potential molecular marker for predicting COVID-19 progression

A SARS-CoV-2 related signature that explores the tumor microenvironment and predicts immunotherapy response in esophageal squamous cell cancer

Multi-omics analyses of tumor-associated immune-infiltrating cells with the novel immune checkpoint protein tyrosine phosphatase 1B (PTP1B) in extracellular matrix of brain-lower-grade-glioma (LGG) and uveal-melanoma (UVM)

Contact Info

Product

Resources

About